MYD88 and diffuse large B-cell lymphoma: MYD88 mutated PT-DLBCL and systemic DLBCL patients showed similar prognoses (Fig. 2F, Supplementary Fig. 4C) and fewer numbers of DEGs than in the entire cohort (Fig. 2H, Supplementary Table 8, Supplementary Fig. 4D).